Studies on the mechanism of action of 1-β-D-arabinofuranosyl-5-azacytosine (fazarabine) in mammalian lymphoblasts

Journal of Experimental Therapeutics and Oncology

Volumn 1, Issue 3, 1996, Pages 191-203

  Barchi Jr , J J ^a   Cooney, D A ^a   Ahluwalia, G S ^a   Gharehbaghi, K ^b   Covey, J M ^a   Hochman, I ^a   Paull, K D ^a   Jayaram, H N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

DNA incorporation; Fazarabine; Mechanism of action; P388 and Molt 4 lymphoblasts; Phosphorylation

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DEOXYCYTIDINE; DNA; DRUG DERIVATIVE; FAZARABINE;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; LEUKEMIA P 388; LYMPHOCYTE; METABOLISM; MOUSE; MOUSE STRAIN; PHOSPHORYLATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CELL SURVIVAL; DEOXYCYTIDINE; DNA, NEOPLASM; HUMANS; LEUKEMIA P388; LYMPHOCYTES; MICE; MICE, INBRED STRAINS; PHOSPHORYLATION; TUMOR CELLS, CULTURED;

EID: 0030132023     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Beisler JA, Abbasi MM, Driscoll JS. The synthesis and anti-tumor activity of arabinosyl-5-azacytosine. Biochem Pharmacol 26: 2469-2472, 1977.
2. Beisler JA. Isolation, characterization and properties of a labile hydrolysis product of the antitumor nucleoside, 5-azacytidine. J Med Chem 21: 204-208, 1978.
3. Dalal M, Plowman J, Breitman TR, et al. Arabinosyl-5-azacytosine I: Antitumor and cytotoxic properties. Cancer Res 46: 831-838, 1986.
4. Wallace RE, Lindth D, Durr FE. Arabinosyl-5-azacytosine activity against human tumors in athymic mice. Cancer Chemother Pharmacol 25: 117-123, 1989.
5. Yang GS, McCulloch EA. A comparison of lethal effect in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells of acute myeloblastic leukemia. Hematol Pathol 6: 125-130, 1992.
6. Heideman RL, Gillespie A, Ford H, et al. Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res 49: 5213-5216, 1989.
7. Ben-Baruch N, Denicoff AM, Goldspiel BR, O'Shaughnessy JA, Cowen KH. Phase-II study of fazarabine (NSC 281272) in patients with metastatic colon carcinoma. Invest New Drugs 11: 71-74, 1993.
8. Bailey H, Tutsch KD, Arzomaninan RZ, Tombes MB, Alberti D, Bruggink J, Wilding G. Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion. Cancer Res 51: 1105-1108, 1991.
9. Ho DH, Brown N, Lin JR, et al. Clinical pharmacology of 1-β-D-arabinofuranosyl-5-azacytosine (fazarabine) following 72-hour infusion. Drug Metab Disp 19: 643-664, 1991.
10. Townsend A, Leclerc JM, Dutchman G, Cooney DA, Cheng Y-C. Metabolism of 1-β-D-arabinofuranosyl-5-azacytosine and incorporation into DNA of human T-lymphoblast cells (Molt-4). Cancer Res 45: 3522-3528, 1985.
11. Ahluwalia GS, Cohen M, Kang G, et al. Arabinosyl-5-azacytosine III: Mechanism of native and acquired resistance. Cancer Res 46: 4479-4485, 1986.
12. Paull KD, Hamel E, Malspeis L. The prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. In: Foye WO ed. Cancer Chemotherapeutic Agents, Washington:ACS 9-45, 1995.
13. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drugs screen utilizing a diverse panel of human tumor cell lines in culture. J Natl Cancer Inst 83: 757-766, 1991.
14. Glazer RI, Knode, MC. 1-β-D-Arabinosyl-5-azacytosine: cytocidal activity and effects on the synthesis and methylation of DNA in human colon carcinoma cells. Mol Pharmocol 26: 381-387, 1984.
15. Pithová P, Piskala A, Pitha J, Šorm F. Nucleic Acids Components and Their Analogues. LXVI. Hydrolysis of 5-azacytidine and its Connection with Biological Activity. Coll Czech Chem Comm 30: 2801-2811, 1965.
16. Singh P, Hodgson DJ. The crystal and molecular structure of α-D-ribofurano[1′,2′:4,5]-2-oxazolidone, a decomposition product of 5-azacytidine. Acta Cryst B32: 2329-2333, 1976.
17. Lin K-T, Momparler RL, Rivard GE. High-performance liquid Chromatographie analysis of chemical stability of 5-aza-2′-deoxycytidine. J Pharm Sci 70: 1228-1232, 1981.
18. Covey JM, D'Lncalei M, Tilchen EJ, Zaharko DS, Kohn, KW. Differences in DNA damage produced by 5-aza-2′-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res 46: 5511-5517, 1986.
19. Barchi JJ Jr, Musser S, Marquez VE. The decomposition of 1-(β-D-ribofuranosyl)-1,2-dihydropyrimidin-2-one (zebularine) in alkali: mechanism and products. J Org Chem 57: 536-541, 1992.
20. Beisler JA, Abbasi MM, Driscoll JS. Synthesis and anti-tumor activity of 5-azacytosine arabinose. J Med Chem 10: 1230-1234, 1979.
21. Avramis VI, Powell WC, Mecum RA. Cellular metabolism of 1-β-D-arabinofuranosyl-5-azacytidine and incorporation into DNA and RNA of human lymphoid CEM/O and CEM/deoxycytidine kinase deficient cells. Cancer Chemother Pharmacol 25: 19-24, 1989.